Study Evaluating the Safety and Efficacy of a Once-daily Dose of Tigecycline vs Ertapenem in Diabetic Foot Infections (DFI) With a Substudy in Patients With Diabetic Foot Infections Complicated by Osteomyelitis.

ClinicalTrials.gov ID: NCT00366249

Public ClinicalTrials.gov record NCT00366249. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 22, 2026, 3:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-Blind, Comparison Study of the Safety and Efficacy of a Once-Daily Dose of Tigecycline Versus Ertapenem for the Treatment of Foot Infections in Subjects With Diabetes

Study identification

NCT ID: NCT00366249
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Enrollment: 1,061 participants

Conditions and interventions

Conditions

Interventions

Tigecycline Drug
Ertapenem Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 31, 2006
Primary completion: Feb 28, 2009
Completion: Feb 28, 2009
Last update posted: Apr 27, 2010

2007 – 2009

United States locations

U.S. sites: 26
U.S. states: 12
U.S. cities: 23

Facility	City	State	ZIP	Site status
Not listed	Los Angeles	California	90010	—
Not listed	Los Angeles	California	91342	—
Not listed	Northridge	California	91326	—
Not listed	San Francisco	California	94115	—
Not listed	Sylmar	California	91342	—
Not listed	Torrance	California	90502	—
Not listed	Orlando	Florida	32801	—
Not listed	Orlando	Florida	32806	—
Not listed	Pensacola	Florida	32501	—
Not listed	West Palm Beach	Florida	33407	—
Not listed	Honolulu	Hawaii	96814	—
Not listed	Chicago	Illinois	60637	—
Not listed	Evanston	Illinois	60201	—
Not listed	North Chicago	Illinois	60064	—
Not listed	Springfield	Illinois	62701	—
Not listed	Springfield	Illinois	62791	—
Not listed	Baltimore	Maryland	21224	—
Not listed	Boston	Massachusetts	02215	—
Not listed	Somers Point	New Jersey	08244	—
Not listed	Winston-Salem	North Carolina	27103	—
Not listed	Lima	Ohio	45801	—
Not listed	Toledo	Ohio	43614	—
Not listed	West Reading	Pennsylvania	19610	—
Not listed	Columbia	South Carolina	29203	—
Not listed	Dallas	Texas	75203	—
Not listed	San Antonio	Texas	78229	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 185 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00366249, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 27, 2010 · Synced Jul 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00366249 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →